Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.

Typeset version

 

TY  - JOUR
AU  - Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AV
PY  - 2009
C2  - January
T2  - Cell Host and Microbe
TI  - Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.
AV  - Published
C1  - Not Avail. ()
NV  - 5
IS  - 1
SP  - 95
EP  - 105
AB  - Protecting against both liver and blood stages of infection is a long-sought goal of malaria vaccine design. Recently, we described the use of replication-defective viral vaccine vectors expressing the malaria antigen merozoite surface protein-1 (MSP-1) as an antimalarial vaccine strategy that elicits potent and protective antibody responses against blood-stage parasites. Here, we show that vaccine-induced MSP-1-specific CD4(+) T cells provide essential help for protective B cell responses, and CD8(+) T cells mediate significant antiparasitic activity against liver-stage parasites. Enhanced survival is subsequently seen in immunized mice following challenge with sporozoites, which mimics the natural route of infection more closely than when using infected red blood cells. This effect is evident both in the presence and absence of protective antibodies and is associated with decreased parasite burden in the liver followed by enhanced induction of the cytokine IFN-gamma in the serum. Multistage immunity against malaria can thus be achieved by using viral vectors recombinant for MSP-1.
UR  - http://www.cell.com/cell-host-microbe/retrieve/pii/S1931312808004034
L3  - 10.1016/j.chom.2008.12.004
DA  - 2009/01
ER  - 
@article{V16245990,
  author = {Draper SJ,  Goodman AL and  Biswas S,  Forbes EK and  Moore AC,  Gilbert SC and  Hill AV },
  year = {2009},
  month = {January},
  JOURNAL = {{Cell Host and Microbe}},
  TITLE = {{Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.}},
  status = {Published},
  note = {Citations: {Not Avail. ()}},
  volume = {5},
  number = {1},
  pages = {95--105},
  ABSTRACT = {{Protecting against both liver and blood stages of infection is a long-sought goal of malaria vaccine design. Recently, we described the use of replication-defective viral vaccine vectors expressing the malaria antigen merozoite surface protein-1 (MSP-1) as an antimalarial vaccine strategy that elicits potent and protective antibody responses against blood-stage parasites. Here, we show that vaccine-induced MSP-1-specific CD4(+) T cells provide essential help for protective B cell responses, and CD8(+) T cells mediate significant antiparasitic activity against liver-stage parasites. Enhanced survival is subsequently seen in immunized mice following challenge with sporozoites, which mimics the natural route of infection more closely than when using infected red blood cells. This effect is evident both in the presence and absence of protective antibodies and is associated with decreased parasite burden in the liver followed by enhanced induction of the cytokine IFN-gamma in the serum. Multistage immunity against malaria can thus be achieved by using viral vectors recombinant for MSP-1.}},
  url = {http://www.cell.com/cell-host-microbe/retrieve/pii/S1931312808004034},
  doi = {10.1016/j.chom.2008.12.004},
  source = {IRIS}
}
AUTHORSAUauthorDraper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AV
YEARPYyear2009
MONTHC2monthJanuary
JOURNAL_CODET2journalCell Host and Microbe
TITLETItitleRecombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.
STATUSAVstatusPublished
TIMES_CITEDC1citationsNot Avail. ()
SEARCH_KEYWORDKWkeywords
VOLUMENVvolume5
ISSUEISnumber1
START_PAGESPpages95
END_PAGEEPpages105
ABSTRACTABabstractProtecting against both liver and blood stages of infection is a long-sought goal of malaria vaccine design. Recently, we described the use of replication-defective viral vaccine vectors expressing the malaria antigen merozoite surface protein-1 (MSP-1) as an antimalarial vaccine strategy that elicits potent and protective antibody responses against blood-stage parasites. Here, we show that vaccine-induced MSP-1-specific CD4(+) T cells provide essential help for protective B cell responses, and CD8(+) T cells mediate significant antiparasitic activity against liver-stage parasites. Enhanced survival is subsequently seen in immunized mice following challenge with sporozoites, which mimics the natural route of infection more closely than when using infected red blood cells. This effect is evident both in the presence and absence of protective antibodies and is associated with decreased parasite burden in the liver followed by enhanced induction of the cytokine IFN-gamma in the serum. Multistage immunity against malaria can thus be achieved by using viral vectors recombinant for MSP-1.
PUBLISHER_LOCATIONCYaddress
ISBN_ISSNSNisbn
EDITIONETedition
URLURurlhttp://www.cell.com/cell-host-microbe/retrieve/pii/S1931312808004034
DOI_LINKL3doi10.1016/j.chom.2008.12.004
FUNDING_BODYM2note
GRANT_DETAILSM2note